Brain Abscess and Empyema
Brain abscess is a focal collection of infected material within the brain parenchyma, evolving through stages from cerebritis to an encapsulated lesion. Despite advances in neuroimaging and antimicrobial therapy, brain abscess remains a serious condition with mortality rates of 5–15% and significant morbidity. Subdural empyema, an infection between the dura and arachnoid, represents a distinct neurosurgical emergency with rapid progression if not evacuated promptly. Accurate diagnosis hinges on recognizing characteristic imaging findings — particularly restricted diffusion on MRI — and understanding the microbiology, which varies based on the source of infection.
Bottom Line
- DWI is the key: Brain abscess shows restricted diffusion (bright on DWI, dark on ADC) — this distinguishes abscess from ring-enhancing tumors, which typically do not restrict
- Streptococcus species are #1: Especially the S. anginosus/intermedius/constellatus (milleri) group; polymicrobial infections are common with otogenic and dental sources
- Classic triad is uncommon: Headache + fever + focal deficit present in only ~20% of cases; headache alone is the most common symptom
- Source determines microbiology: Contiguous spread (sinusitis, otitis, dental) vs. hematogenous (endocarditis, pulmonary AVM, right-to-left shunt) vs. post-surgical
- Surgery is usually needed: Aspiration or excision for lesions >2.5 cm; medical therapy alone may suffice for small (<2.5 cm), multiple, or surgically inaccessible lesions in early cerebritis
- Subdural empyema is a neurosurgical emergency: Rapidly progressive; requires urgent surgical evacuation — medical therapy alone is insufficient
Pathogenesis and Etiology
Brain abscess develops through three principal mechanisms: contiguous spread from a parameningeal focus, hematogenous seeding, or direct inoculation. In approximately 20% of cases, no source is identified (cryptogenic).
| Mechanism | Source | Typical Location | Common Organisms |
|---|---|---|---|
| Contiguous spread | Sinusitis (frontal, ethmoid) | Frontal lobe | Streptococci, anaerobes, Haemophilus, Staphylococcus |
| Otitis media / mastoiditis | Temporal lobe, cerebellum | Streptococci, Bacteroides, Pseudomonas, Enterobacteriaceae | |
| Dental infection | Frontal lobe | Streptococci (especially S. anginosus group), Fusobacterium, Bacteroides | |
| Hematogenous | Infective endocarditis | MCA distribution (multiple) | S. aureus, Streptococcus viridans |
| Pulmonary infection/abscess | Multiple (gray-white junction) | Streptococci, Fusobacterium, Actinomyces | |
| Right-to-left cardiac shunt (e.g., Osler-Weber-Rendu, cyanotic heart disease) | Multiple | Streptococci; often polymicrobial | |
| Direct inoculation | Neurosurgery, penetrating trauma | Operative site | S. aureus, Enterobacteriaceae, Pseudomonas |
| Cryptogenic | No identified source (~20%) | Variable | Streptococci, mixed flora |
Microbiology
- Streptococcus species: Most common overall (~35–50%), especially the S. anginosus group (formerly S. milleri) — S. intermedius, S. anginosus, and S. constellatus; these organisms have a unique propensity to cause abscess formation
- Anaerobes: Bacteroides fragilis, Fusobacterium, Prevotella, Peptostreptococcus — particularly common with otogenic and dental sources; frequently part of polymicrobial infections
- Staphylococcus aureus: ~15–20%; associated with post-surgical, post-traumatic, and endocarditis-related abscesses; MRSA increasingly common
- Gram-negative bacilli: Enterobacteriaceae, Pseudomonas — otogenic source and post-surgical cases
- Polymicrobial: Found in 20–30% of cases; especially common with contiguous spread from dental or otic foci
Immunocompromised Hosts — Special Organisms
- Toxoplasma gondii: Most common cause of brain abscess in HIV/AIDS (CD4 <100); multiple ring-enhancing lesions with predilection for basal ganglia; empiric treatment trial standard of care
- Nocardia species: Transplant recipients, chronic corticosteroid use; may be multiloculated; sulfonamides are first-line treatment
- Aspergillus species: Hematologic malignancy, transplant; angioinvasive with hemorrhagic transformation; high mortality (>50%)
- Mucor/Rhizopus (mucormycosis): Diabetic ketoacidosis, neutropenia; rhinocerebral form extends from sinuses; black eschar on palate; emergent surgical debridement + amphotericin B
- Mycobacterium tuberculosis: Tuberculoma; usually in endemic areas or immunocompromised; may present as ring-enhancing or solid lesion
- Listeria monocytogenes: Rhombencephalitis (brainstem abscess); immunocompromised and elderly
Clinical Presentation
The clinical presentation of brain abscess is often insidious, developing over days to weeks. Symptoms reflect the combination of a space-occupying lesion and infection, though systemic signs of infection are frequently absent.
- Headache: Most common symptom (70–80%); typically progressive, localized, and worse in the morning or with Valsalva maneuvers
- Fever: Present in only ~50% of patients — its absence should not dissuade from the diagnosis
- Focal neurologic deficits: 50–65%; depends on lesion location (hemiparesis, aphasia, visual field cuts, cerebellar signs)
- Seizures: 25–35%; may be focal or generalized
- Altered mental status: 40–50%; ranges from confusion to obtundation
- Nausea/vomiting/papilledema: Signs of elevated ICP; present in 25–40%
- Classic triad (headache + fever + focal deficit): Present in only ~20% of cases
When to Suspect Brain Abscess
- Subacute progressive headache with new neurologic deficits — even without fever
- Known sinusitis, otitis, dental infection, or endocarditis with new CNS symptoms
- Ring-enhancing lesion on imaging — abscess must be in the differential alongside tumor
- Multiple ring-enhancing lesions in immunocompromised patient — consider toxoplasmosis, lymphoma, metastases
- Lumbar puncture is generally contraindicated in suspected brain abscess due to risk of herniation and low diagnostic yield (cultures positive in <25%)
Neuroimaging
Stages of Brain Abscess Evolution
Brain abscess evolves through predictable stages with distinct imaging characteristics at each phase. Understanding these stages guides treatment decisions.
| Stage | Time Frame | CT Appearance | MRI Appearance |
|---|---|---|---|
| Early cerebritis | Days 1–3 | Ill-defined low density; irregular enhancement | T1 hypointense, T2 hyperintense; minimal enhancement; may restrict on DWI |
| Late cerebritis | Days 4–9 | Better-defined low density with ring-like enhancement | Developing ring enhancement; central necrosis begins; restricted diffusion |
| Early capsule | Days 10–14 | Well-defined ring enhancement; central hypodensity | Thin, smooth ring enhancement; T1 hypointense rim (collagen capsule); restricted diffusion centrally |
| Late capsule | >14 days | Thick ring enhancement; reduced surrounding edema | Mature capsule; persistent restricted diffusion; surrounding edema decreasing |
Key MRI Features of Brain Abscess
- DWI/ADC: Restricted diffusion is the hallmark — the abscess cavity is bright on DWI and dark on ADC (due to viscous purulent content with high cellularity); sensitivity ~95%, specificity ~90%
- T1 with gadolinium: Smooth, thin, uniform ring enhancement; the wall is typically thinner on the medial/ventricular side (less vascular)
- T2/FLAIR: Central hyperintensity (pus); capsule may appear as a hypointense rim; surrounding vasogenic edema
- MR spectroscopy: Amino acid peaks (valine, leucine, isoleucine at 0.9 ppm), succinate (2.4 ppm), acetate (1.9 ppm), and lactate — these metabolites are produced by bacteria and are not seen in tumors
- SWI (susceptibility-weighted imaging): Dual rim sign — hypointense outer rim and hyperintense inner rim — characteristic of abscess
Differential Diagnosis of Ring-Enhancing Lesions
| Feature | Brain Abscess | GBM (High-Grade Glioma) | Metastasis | Toxoplasmosis |
|---|---|---|---|---|
| Enhancement wall | Smooth, thin, uniform | Thick, irregular, nodular | Variable; may be smooth or irregular | Ring or nodular; may have eccentric target sign |
| DWI | Restricted (bright) | Usually no restriction (may have mild) | Usually no restriction | May restrict (less consistently) |
| MR spectroscopy | Amino acids, succinate, acetate | High choline, low NAA, lactate | High choline, low NAA | Lactate, lipid peaks |
| Wall vascularity | Thin medial wall (near ventricle) | Irregularly thick wall | Variable | Variable |
| Multiplicity | 25–30% multiple | Usually solitary (can be multifocal) | Often multiple | Multiple, basal ganglia predilection |
| Clinical context | Infection source; fever (50%) | Older adult; progressive symptoms | Known primary malignancy | HIV+, CD4 <100 |
Treatment
Antibiotic Therapy
Empiric antibiotic therapy should be guided by the suspected source of infection. Definitive therapy is based on culture results from aspirated material. Duration of IV antibiotics is typically 6–8 weeks, with serial imaging to monitor response.
| Clinical Scenario | Empiric Regimen | Rationale |
|---|---|---|
| Unknown source / contiguous (sinus, dental, otic) | Ceftriaxone (2 g IV q12h) + metronidazole (500 mg IV q8h) | Covers streptococci, gram-negatives, and anaerobes |
| Post-surgical or post-traumatic | Vancomycin + ceftriaxone + metronidazole (or vancomycin + cefepime/meropenem) | MRSA coverage + broad gram-negative and anaerobic coverage |
| Hematogenous (endocarditis) | Vancomycin + ceftriaxone + metronidazole | S. aureus and streptococcal coverage |
| Immunocompromised (non-HIV) | Vancomycin + ceftriaxone + metronidazole; consider TMP-SMX (Nocardia) or voriconazole (Aspergillus) | Broad coverage including opportunistic organisms |
| HIV/AIDS with ring-enhancing lesions | Empiric toxoplasmosis treatment: pyrimethamine + sulfadiazine + leucovorin for 2 weeks | Treat empirically; biopsy if no improvement at 2 weeks |
Duration and Monitoring of Antibiotic Therapy
- IV antibiotics: 6–8 weeks is standard; some sources recommend 4–6 weeks if fully aspirated and organism identified
- Oral step-down: Increasingly used after initial IV course; fluoroquinolones and metronidazole have good CNS penetration; total treatment duration often 8–12 weeks
- Serial imaging: MRI every 1–2 weeks initially; ring enhancement may persist for months even with successful treatment — follow cavity size and DWI changes
- Inflammatory markers: CRP and ESR can help monitor treatment response
- Antiseizure prophylaxis: Generally recommended during acute phase due to high seizure risk; duration individualized (typically 3–6 months if no seizures occurred)
Surgical Management
Surgical intervention is a critical component of brain abscess management. The decision between aspiration and excision depends on the stage, size, location, and number of abscesses.
| Approach | Indications | Advantages | Limitations |
|---|---|---|---|
| Stereotactic aspiration | Deep or eloquent location; multiple abscesses; poor surgical candidate; diagnostic uncertainty | Less invasive; can be repeated; provides culture material | May not fully evacuate; higher recurrence rate (~15%) |
| Craniotomy and excision | Superficial, accessible lesion; multiloculated abscess; fungal abscess; traumatic abscess with foreign body; failed aspiration | Complete removal; lower recurrence; better for multiloculated lesions | More invasive; risk of neurologic deficit |
| Medical therapy alone | Small (<2.5 cm) abscess; multiple small abscesses; early cerebritis stage; surgically inaccessible; clinical improvement on antibiotics | Avoids surgical risks | No culture data; higher failure rate; requires close imaging follow-up |
Indications for Urgent/Emergent Surgery
- Abscess >2.5 cm with significant mass effect
- Impending or actual herniation: Deteriorating consciousness, pupillary asymmetry
- Intraventricular rupture: Catastrophic complication with mortality >80% without emergent intervention; presents with acute deterioration, meningismus
- Posterior fossa abscess: Risk of rapid brainstem compression and obstructive hydrocephalus
- Failure of medical therapy: Enlarging abscess despite ≥2 weeks of appropriate antibiotics
Subdural Empyema
Subdural empyema is a collection of pus between the dura mater and the arachnoid membrane. It accounts for 15–25% of intracranial infections and is a neurosurgical emergency that requires urgent surgical evacuation. The infection spreads rapidly over the cerebral convexity because there are no anatomic barriers within the subdural space.
Etiology and Epidemiology
- Most common source: Paranasal sinusitis (especially frontal sinusitis) — accounts for 50–70% of cases
- Demographic: Predominantly young males (sinusitis-related); male-to-female ratio ~3:1
- Other sources: Otitis media/mastoiditis, post-surgical, post-traumatic, hematogenous (rare)
- Microbiology: Streptococci (especially S. anginosus group), anaerobes, staphylococci; polymicrobial in ~30%
Clinical Features
- Rapid deterioration: Unlike brain abscess, subdural empyema progresses quickly over hours to days
- Fever and headache: Almost universally present
- Focal neurologic deficits: Hemiparesis, aphasia (often disproportionate to the size of the collection)
- Seizures: Very common (50–80%); often focal with secondary generalization
- Meningeal signs: Nuchal rigidity common due to meningeal irritation
- Signs of elevated ICP: Obtundation, papilledema
Subdural Empyema — Imaging and Management
- MRI with contrast: Gold standard — crescentic extra-axial collection with peripheral enhancement; restricted diffusion on DWI (distinguishes from sterile effusion)
- CT with contrast: May show hypodense collection with rim enhancement; less sensitive than MRI, especially for early or small collections
- Treatment: Emergent surgical evacuation (craniotomy preferred over burr holes for better drainage) + prolonged IV antibiotics (4–6 weeks)
- Empiric antibiotics: Vancomycin + ceftriaxone + metronidazole (same as brain abscess regimen)
- Prognosis: Mortality 10–20% with prompt surgery; >50% if surgery delayed; neurologic sequelae in 15–30% of survivors
Epidural Abscess (Intracranial)
Intracranial epidural abscess (between the skull and dura) is less common and generally less emergent than subdural empyema, as the dura serves as an effective barrier limiting spread.
- Etiology: Most commonly associated with osteomyelitis of the skull (frontal bone from sinusitis), post-craniotomy infection, or extension from mastoiditis
- Presentation: More indolent course compared to subdural empyema; focal headache, low-grade fever, localized tenderness; focal deficits less common
- Pott puffy tumor: Subperiosteal abscess of the frontal bone with associated epidural abscess, arising from frontal sinusitis — presents as forehead swelling with tenderness
- Imaging: Lenticular (biconvex) extra-axial collection with peripheral enhancement; may see associated calvarial osteomyelitis
- Treatment: Surgical drainage + antibiotics; less emergent than subdural empyema but still requires definitive surgical management; treat underlying osteomyelitis
Prognosis and Follow-Up
| Factor | Favorable Prognosis | Poor Prognosis |
|---|---|---|
| GCS at presentation | GCS ≥13 | GCS <9 (mortality approaches 50–80%) |
| Number of abscesses | Solitary | Multiple |
| Location | Superficial, non-eloquent | Deep, brainstem, intraventricular rupture |
| Organism | Streptococci (respond well to antibiotics) | Fungal (especially Aspergillus); mortality >50% |
| Immune status | Immunocompetent | Immunocompromised (higher mortality, atypical organisms) |
| Time to treatment | Early diagnosis and treatment | Delayed diagnosis; ruptured abscess |
- Overall mortality: 5–15% with modern treatment (higher for fungal abscesses and intraventricular rupture)
- Seizure risk: 30–50% develop epilepsy during follow-up; antiseizure medication typically continued for at least 3–6 months and sometimes indefinitely if seizures occur
- Neurologic sequelae: 20–50% of survivors have persistent deficits (hemiparesis, cognitive impairment, epilepsy)
- Follow-up imaging: Serial MRI every 2–4 weeks until resolution; ring enhancement may persist for months after clinical cure — follow cavity size and diffusion characteristics
- Source investigation: Complete evaluation for the source of infection is essential — echocardiography for endocarditis, CT sinuses/temporal bones, dental evaluation, evaluation for right-to-left shunt (bubble study)
References
- Brouwer MC, Coutinho JM, van de Beek D. Clinical characteristics and outcome of brain abscess: systematic review and meta-analysis. Neurology. 2014;82(9):806-813.
- Bokhari MR, Mesfin FB. Brain abscess. In: StatPearls. StatPearls Publishing; 2024.
- Nathoo N, Nadvi SS, Narotam PK, van Dellen JR. Brain abscess: management and outcome analysis of a computed tomography era experience with 973 patients. World Neurosurg. 2011;75(5-6):716-726.
- Sonneville R, Ruimy R, Benzonana N, et al. An update on bacterial brain abscess in immunocompetent patients. Clin Microbiol Infect. 2017;23(9):614-620.
- Erdogan E, Cansever T. Pyogenic brain abscess. Neurosurg Focus. 2008;24(6):E2.
- Mathisen GE, Johnson JP. Brain abscess. Clin Infect Dis. 1997;25(4):763-779.
- Leuthardt EC, Wippold FJ 2nd, Oswood MC, Rich KM. Diffusion-weighted MR imaging in the preoperative assessment of brain abscesses. Surg Neurol. 2002;58(6):395-402.
- Arlotti M, Grossi P, Pea F, et al. Consensus document on controversial issues for the treatment of infections of the central nervous system: bacterial brain abscesses. Int J Infect Dis. 2010;14(Suppl 4):S79-S92.
- Brouwer MC, Tunkel AR, McKhann GM 2nd, van de Beek D. Brain abscess. N Engl J Med. 2014;371(5):447-456.
- Dill SR, Cobbs CG, McDonald CK. Subdural empyema: analysis of 32 cases and review. Clin Infect Dis. 1995;20(2):372-386.
- Osborn MK, Steinberg JP. Subdural empyema and other suppurative complications of paranasal sinusitis. Lancet Infect Dis. 2007;7(1):62-67.
- Patel K, Clifford DB. Bacterial brain abscess. Neurohospitalist. 2014;4(4):196-204.
- Muzumdar D, Jhawar S, Goel A. Brain abscess: an overview. Int J Surg. 2011;9(2):136-144.
- Menon S, Bharadwaj R, Chowdhary A, et al. Current epidemiology of intracranial abscesses: a prospective 5 year study. J Med Microbiol. 2008;57(Pt 10):1259-1268.
- Landriel F, Ajler P, Hem S, et al. Supratentorial and infratentorial brain abscesses: surgical treatment, complications, and outcomes — a 10-year single-center study. Acta Neurochir (Wien). 2012;154(5):903-911.